Oaklander welcomed the news of the approval of the new vaccine, saying that more adults should be vaccinated against shingles. In the United States alone, there are an estimated 1 million cases of shingles a year, and one in three people can expected to develop the condition during their lifetime.
6 brokerages have issued twelve-month price objectives for Arbutus Biopharma Corp's shares. Their forecasts range from $5.00 to $10.00. On average, they anticipate Arbutus Biopharma Corp's stock price to reach $7.00 in the next year.
Shares in Australiaâs biggest bio-pharmaceutical company, CSL Ltd [ASX:CSL] slumped by 7.8% today, to close at $82.95. The slump puts the brakes on an impressive rally from $65 mid last year. The company produced a net profit rise of 7.1% for the half-year ending in December.